UPDATE: Jefferies Reiterates On Auxilium Pharmaceuticals Following AUA Meeting
UPDATE: Jefferies Reiterates on OncoMed Pharmaceuticals as CELG Collaboration Validates OMED's Platform and Pipeline
UPDATE: Jefferies Reiterates On Auxilium Pharmaceuticals Following AUA Meeting
UPDATE: Jefferies Reiterates on OncoMed Pharmaceuticals as CELG Collaboration Validates OMED's Platform and Pipeline
Jefferies Reiterates on Dynavax Technologies Awaiting Initiation of HBV-23 Safety Trial
Jefferies Reiterates Buy on Amarin Corporation on Continued Positive Outlook
Jefferies Reiterates on Dynavax Technologies Awaiting Initiation of HBV-23 Safety Trial
Jefferies Reiterates Buy on Amarin Corporation on Continued Positive Outlook
UPDATE: Jefferies Initiates Coverage on Stemline Therapeutics Ahead of SL-401 Trials
UPDATE: Jefferies Raises PT on Incyte Following Favorable Phase 2 RECAP Data
Thomas Wei Recent News
UPDATE: Jefferies Initiates OncoMed Pharmaceuticals at Buy on Market Leader Position
UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership Discussion
UPDATE: Jefferies Lowers PT on Dynavax Technologies Following Major FDA Setback
UPDATE: Jefferies Lowers PT on Rigel Pharmaceuticals Following Return of Fostamatinib Rights
UPDATE: Jefferies Initiates Lexicon Pharmaceuticals at Buy on Class-Leading SGLT Inhibitor
Benzinga’s Volume Movers (TLCR, RYAAY, CELG, GOLD)
Benzinga’s Top Pre-Market Gainers (TLCR, BPAX, CELG, EGLE, ARMH)
Jefferies & Company Raises Incyte (INCY) Target Price To $19
Jefferies & Company Raises ViroPharma (VPHM) Price Target To $18
Jefferies & Company Maintains Auxilium Pharmaceuticals (AUXL) Buy Rating